SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

EOLS: Q3 revenue rose 13%, with positive Adjusted EBITDA for a fourth straight quarter

Evolus reported that third-quarter revenue rose 13% year over year to $78.0 million. Adjusted EBITDA, a measure of operating performance that excludes certain items, was positive for the fourth consecutive quarter. The company reaffirmed its fiscal 2026 revenue guidance and lowered its operating expense guidance.

Published:

Updated:

What happened

Evolus reported that third-quarter revenue rose 13% from a year earlier to $78 million. Revenue grew in both its toxin and injectable gel businesses. Adjusted EBITDA, a measure of earnings that leaves out certain costs, was positive for a fourth straight quarter. The company kept its revenue guidance and lowered its operating expense guidance.

Global impact / market context

Revenue growth and repeated positive adjusted EBITDA show that the company reported continued sales growth and positive results on this measure. Lower operating expense guidance could mean it expects to spend less than previously planned. The supplied facts include no market reaction.

What to watch

  1. Check whether revenue continues to grow; the reported increase was 13% from a year earlier.
  2. Check whether adjusted EBITDA stays positive; this was the fourth positive quarter in a row.
  3. Check future operating expense guidance; the company lowered it while keeping its revenue guidance.

Affected assets

  • Evolus, Inc.

Evidence